The almighty oracle has spoken! [RSABE / ABEL]

posted by Helmut Homepage – Vienna, Austria, 2015-07-23 21:54 (2253 d 04:45 ago) – Posting: # 15139
Views: 24,343

Dear Dan et alii,

today the EMA published Rev. 12 of the Q&A-document (dated 25 June). See #23

Suitability of a 3-period replicate design scheme for the
demonstration of within-subject variability for Cmax

Essentially it says that CVwR is a “key parameter” and according to the GL a minimum of 12 subjects is needed for a “valid” BE study. In other words – and contrary to what the “leading European regulatory authority” told you – TRT|RTR is indeed acceptable if (‼) at least 12 subjects complete the RTR sequence.

Given the commonly applied T/R-ratio of 0.90 for HVD(P)s and ≥80% power this issue is practically not rele­vant. Full throttle for any study – unless you expect a lot (≥42%) of dropouts!

CVwR   N  nRTR  do.ratemax (%)
 25   42   21      42.9
 30   50   25      52.0
 40   40   20      47.8
 50   42   21      42.9
 60   48   24      50.0
 70   60   30      60.0
 80   74   37      67.6


[image]

[image]

Parturient montes, nascetur ridiculus mus. Horace (Ars poetica, Ep.II.3, 139)

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,691 posts in 4,534 threads, 1,541 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Thursday 02:40 UTC (Europe/Vienna)

Learning is a lifetime process, but there comes a time
when we must stop adding and start updating.    Robert Brault

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5